Loading...
XWAR
SLV
Market cap138mUSD
Jun 11, Last price  
27.70PLN
Name

Selvita SA

Chart & Performance

D1W1MN
P/E
P/S
1.49
EPS
Div Yield, %
Shrs. gr., 5y
28.39%
Rev. gr., 5y
62.22%
Revenues
342m
-1.43%
41,028,64148,133,12754,573,74070,678,63930,443,469137,356,285310,920,815407,462,000346,957,000342,007,000
Net income
-6m
L
6,269,8112,720,2113,926,48510,496,4885,523,00217,998,07814,899,00030,309,00069,878,000-6,098,000
CFO
64m
-18.88%
-16,429,766-6,280,11210,538,65911,595,2824,299,16429,356,20387,472,02675,430,00078,980,00064,069,000

Profile

Selvita S.A. operates as a contract research organization in Poland, rest of Europe, the United States, and internationally. It operates in two segments, Contract Research Organization (CRO) services, and Bioinformatics. The company offers drug discovery services in the areas of assay development and screening, medicinal and synthetic chemistry, computer-aided drug design/ artificial intelligence, structural biology, in vitro/ In Vivo pharmacology, ADME/DMPK and analytical testing. It also provides pharma services in the field of drug testing and bioanalytical analysis, including development and optimization, validation and transfer, stability studies, quality control, and regulatory aspects support services. In addition, the company offers research and development services in the areas of process research, laboratory scale custom synthesis of NCEs, industrial chemistry, and synthesis of isotopically labelled compounds, as well as other services for the agrochemical industry. Further, it provides bio-data science and advanced software services to data-driven life science and healthcare organizations. Selvita S.A. was founded in 2007 and is headquartered in Krakow, Poland.
IPO date
Oct 16, 2019
Employees
847
Domiciled in
PL
Incorporated in
PL

Valuation

Title
PLN in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
342,007
-1.43%
346,957
-14.85%
407,462
31.05%
Cost of revenue
74,190
71,158
75,796
Unusual Expense (Income)
NOPBT
267,817
275,799
331,666
NOPBT Margin
78.31%
79.49%
81.40%
Operating Taxes
(4,356)
(2,675)
7,599
Tax Rate
2.29%
NOPAT
272,173
278,474
324,067
Net income
(6,098)
-108.73%
69,878
130.55%
30,309
103.43%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
142,713
46,893
41,464
Long-term debt
175,324
270,032
258,615
Deferred revenue
34,708
33,011
11,020
Other long-term liabilities
810
989
239
Net debt
295,525
200,647
225,829
Cash flow
Cash from operating activities
64,069
78,980
75,430
CAPEX
(18,710)
(73,934)
(101,586)
Cash from investing activities
(36,873)
(65,213)
(79,789)
Cash from financing activities
(57,342)
(30,968)
(5,672)
FCF
266,935
222,751
191,905
Balance
Cash
22,512
52,965
76,175
Long term investments
63,313
(1,925)
Excess cash
5,412
98,930
53,877
Stockholders' equity
147,286
240,623
186,713
Invested Capital
570,520
486,886
441,015
ROIC
51.48%
60.02%
88.26%
ROCE
46.24%
46.79%
66.17%
EV
Common stock shares outstanding
18,355
18,355
18,355
Price
Market cap
EV
EBITDA
320,916
321,251
368,494
EV/EBITDA
Interest
12,655
11,826
4,196
Interest/NOPBT
4.73%
4.29%
1.27%